Ross River virus (RRV) is a mosquito-borne member of the genus Alphavirus that causes epidemic polyarthritis in humans, costing the Australian health system at least US$10 million annually. Recent progress in RRV vaccine development requires accurate assessment of RRV genetic diversity and evolution, particularly as they may affect the utility of future vaccination. In this study, we provide novel RRV genome sequences and investigate the evolutionary dynamics of RRV from timestructured E2 gene datasets. Our analysis indicates that, although RRV evolves at a similar rate to other alphaviruses (mean evolutionary rate of approx. 8¾10"4 nucleotide substitutions per site year "1 ), the relative genetic diversity of RRV has been continuously low through time, possibly as a result of purifying selection imposed by replication in a wide range of natural host and vector species. Together, these findings suggest that vaccination against RRV is unlikely to result in the rapid antigenic evolution that could compromise the future efficacy of current RRV vaccines.
INTRODUCTIONRoss River virus (RRV) is an alphavirus that infects a wide range of vertebrate hosts, including marsupials, equids, rodents, birds and fruit bats, and has multiple mosquito vectors, including several Aedes species (reviewed by Russell, 2002). Of the natural hosts, only humans and horses are known to develop symptoms (Doherty et al., 1963(Doherty et al., , 1972Azuolas et al., 2003). The disease in humans is known as epidemic polyarthritis (EPA) (Shope & Anderson, 1960) and is characterized by polyarthralgia in the small joints, principally of the hands and feet, as well as fever, rash and a range of other non-specific signs and symptoms. Patients may be incapacitated for several weeks after infection, but symptoms diminish in severity in the ensuing 30-40 weeks, leading to a full recovery. Up to approximately 7800 cases are reported annually from Australia (Australian Department of Health and Ageing, 2009) and an epidemic of RRV infection in the Pacific in 1979 and 1980 resulted in tens of thousands of clinical infections (Aaskov et al., 1981;Rosen et al., 1981; Tesh et al., 1981). Importantly, the Pacific epidemic of 1979-1980 suggests strongly that RRV is not dependent on purely sylvatic transmission cycles, and that urban transmission cycles are both possible and expected.Recently, there has been considerable interest in developing a vaccine against RRV infection (Yu & Aaskov, 1994;Aaskov et al., 1997;Kistner et al., 2007) as there is no cure for EPA, because RRV infections appear to confer lifelong immunity against a second clinical infection (Fraser, 1986) and because EPA has been estimated to cost the Australian health system more than US$10 million annually in direct medical costs (Aaskov et al., 1998), with millions more spent on mosquito control. Effective vaccination, whether by live-attenuated virus or inactivated virus, such as the formaldehyde-inactivated virus vaccine currently in development (Kistner et al., 2007), requires that circulat...